Will breakfast or heartburn pills change how this new drug works?

NCT ID NCT07643272

Ongoing Knowledge-focused Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This early-stage study will enroll 24 healthy adults to find out if food or the stomach-acid-reducing drug rabeprazole changes how the body absorbs an experimental drug called HMPL-760. Participants will take HMPL-760 under different conditions (fasting, with a high-fat meal, with a light meal, or with rabeprazole) and have their blood tested. The results will guide how HMPL-760 should be taken in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMPL-760 (an experimental drug) and rabeprazole (a stomach acid reducer)
What this could lead to: If successful, this study will help determine how HMPL-760 should be taken (with or without food, and with or without acid-reducing drugs) in future trials.
What could go wrong: This is a very early Phase 1 study in only 24 healthy people, not patients. It is designed to measure drug levels, not to test if the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Shanghai Xuhui Central Hospital

Shanghai, Shanghai Municipality, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.